A study of evaluating the efficacy between a new drug (Donanemab) compared to an established treatment (Galantamine) in Alzheimer’s disease

Abstract

A combination of symptomatic and disease-modifying therapy approaches are necessary for Alzheimer's disease (AD), a progressive neurological illness. This thesis examines the safety, pharmacokinetics, and clinical effectiveness of galantamine, a well-known cholinesterase inhibitor, and donanemab, a new anti-amyloid monoclonal antibody, in the treatment of AD. Major biological databases were used to perform a thorough narrative review of long-term randomized studies and Phase I–III clinical trials. Despite manageable safety concerns, such as amyloid-related imaging abnormalities, the results show that donanemab significantly reduces amyloid plaque and is linked to a clinically meaningful slowing of cognitive and functional deterioration in early AD. Galantamine, on the other hand, has a proven safety profile, preserves cognition and everyday functioning, and exhibits consistent long-term symptomatic improvements without changing illness. Overall, this study emphasizes how new disease-modifying medications and conventional symptomatic treatments complement one another, underscoring the significance of tailored therapeutic approaches in the changing management of Alzheimer's disease.